Literature DB >> 14646363

Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure.

Masami Satoh1, Hideo Hayashi, Maki Watanabe, Kyoko Ueda, Hideyuki Yamato, Toshimasa Yoshioka, Masaru Motojima.   

Abstract

Uremic toxins have been suggested to promote progression of chronic renal failure by damaging tubular cells. Previous in vitro studies have indicated that some uremic toxins induce oxidative stress and activate NF-kappaB to upregulate plasminogen activator inhibitor-1 in tubular cells. These mechanisms may promote tubulointerstitial fibrosis. The present study examined whether uremic toxins induce glomerular and tubulointerstitial damage in vivo. Two uremic toxins, hippuric acid (HA) or indoleacetic acid (IAA), were tested in two independent experiments (HA-treated rats vs. non-HA-treated controls, IAA-treated rats vs. non-IAA-treated controls). The uremic toxins were administered to subtotally nephrectomized rats. Renal functions were measured periodically and glomerular sclerosis and interstitial fibrosis were examined at the end of the experimental period (18 and 24 weeks, respectively, after subtotal nephrectomy for HA and IAA treatments). Glomerular filtration rate (inulin clearance) at the end of the study period was significantly lower in uremic toxin-treated rats than in control rats (HA-treated rats: 0.090 +/- 0.004 ml/min/100 g body weight vs. non-HA-treated controls: 0.125 +/- 0.013, IAA-treated rats: 0.068 +/- 0.006 versus non-IAA-treated controls: 0.100 +/- 0.013; both p < 0.05). Beta-N-acetyl-glucoseamidase excretion was significantly higher in uremic toxin-treated rats than in control rats (HA-treated: 0.55 +/- 0.05 U/day vs. control: 0.39 +/- 0.04 at week 18, IAA-treated: 0.35 +/- 0.02 vs. control: 0.26 +/- 0.07 at week 16; both p < 0.05). Glomerular sclerosis index was significantly higher in uremic toxin-treated rats than in control rats (HA-treated: 0.85 +/- 0.16 versus control: 0.48 +/- 0.10, IAA-treated: 1.13 +/- 0.25 vs. control: 0.57 +/- 0.10; both p < 0.05). Significant enlargement of interstitial fibrosis was observed in indoleacetic acid-treated rats. These results indicate that overload of uremic toxins accelerates the loss of kidney function, glomerular sclerosis and tubulointerstitial injury in a rat model of chronic renal failure. The present study suggests the potential benefit of early intervention to remove various uremic toxins in delaying the onset of end-stage renal failure in patients with progressive renal disease. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14646363     DOI: 10.1159/000074327

Source DB:  PubMed          Journal:  Nephron Exp Nephrol        ISSN: 1660-2129


  32 in total

Review 1.  The microbiome of the urinary tract--a role beyond infection.

Authors:  Samantha A Whiteside; Hassan Razvi; Sumit Dave; Gregor Reid; Jeremy P Burton
Journal:  Nat Rev Urol       Date:  2015-01-20       Impact factor: 14.432

2.  Effects of probiotic VSL#3 on glomerular filtration rate in dogs affected by chronic kidney disease: A pilot study.

Authors:  Ilaria Lippi; Francesca Perondi; Gianila Ceccherini; Veronica Marchetti; Grazia Guidi
Journal:  Can Vet J       Date:  2017-12       Impact factor: 1.008

Review 3.  The gut microbiota and its relationship with chronic kidney disease.

Authors:  Consuelo Plata; Cristino Cruz; Luz G Cervantes; Victoria Ramírez
Journal:  Int Urol Nephrol       Date:  2019-10-01       Impact factor: 2.370

Review 4.  Uremic toxin and bone metabolism.

Authors:  Yoshiko Iwasaki; Hideyuki Yamato; Tomoko Nii-Kono; Ayako Fujieda; Motoyuki Uchida; Atsuko Hosokawa; Masaru Motojima; Masafumi Fukagawa
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

5.  Differential contributions of rOat1 (Slc22a6) and rOat3 (Slc22a8) to the in vivo renal uptake of uremic toxins in rats.

Authors:  Tsuneo Deguchi; Yousuke Kouno; Tetsuya Terasaki; Akira Takadate; Masaki Otagiri
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

6.  Extendin-4 protects kidney from acute ischemia-reperfusion injury through upregulation of NRF2 signaling.

Authors:  Yen-Yi Zhen; Chih-Chao Yang; Chi-Chih Hung; Chia-Chang Lee; Chen-Chang Lee; Chien-Hsing Wu; Yen-Ta Chen; Wei-Yu Chen; Kuan-Hung Chen; Hon-Kan Yip; Sheung-Fat Ko
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

Review 7.  Gut Microbiota-Kidney Cross-Talk in Acute Kidney Injury.

Authors:  Jing Gong; Sanjeev Noel; Jennifer L Pluznick; Abdel Rahim A Hamad; Hamid Rabb
Journal:  Semin Nephrol       Date:  2019-01       Impact factor: 5.299

Review 8.  The gut microbiome, kidney disease, and targeted interventions.

Authors:  Ali Ramezani; Dominic S Raj
Journal:  J Am Soc Nephrol       Date:  2013-11-14       Impact factor: 10.121

Review 9.  Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target.

Authors:  Ali Ramezani; Ziad A Massy; Björn Meijers; Pieter Evenepoel; Raymond Vanholder; Dominic S Raj
Journal:  Am J Kidney Dis       Date:  2015-11-15       Impact factor: 8.860

Review 10.  Gut microbiome in chronic kidney disease: challenges and opportunities.

Authors:  Anitha Nallu; Shailendra Sharma; Ali Ramezani; Jagadeesan Muralidharan; Dominic Raj
Journal:  Transl Res       Date:  2016-04-30       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.